Jade Biosciences, Inc.
jadebiosciences.comWhat Do They Do?
Develops biologic therapies for people with autoimmune diseases, including antibody candidates for IgA nephropathy, rheumatoid arthritis and other autoimmune disorders.
10-K for FY2025, filed Mar 6, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 6, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$55.8MView ↗
- ▲ +74% (Loss)
- vs −$32.1M in Q2 FY2025
-
Jul 1, 2026
Jade licenses worldwide rights for the JADE301 antibody program
The license covers antibodies against an undisclosed target and includes development and regulatory milestone payments and royalties on product sales.
Sources
8-K, filed Jul 1, 2026
On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon…View ↗
From PAH to autoimmune disease
The older report focused on an inhaled imatinib candidate for pulmonary arterial hypertension; the latest describes antibody candidates for autoimmune diseases, including IgA nephropathy.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 6, 2026We are a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare…View ↗
Who Do They Compete With?
Competes with Otsuka, Novartis, Vera Therapeutics, Vertex, and Climb Bio
10-K for FY2025, filed Mar 6, 2026There is one biologic approved for the treatment of IgAN, sibeprenlimab, which is marketed as Voyxact by Otsuka. There are four small…View ↗
Loading...
